Valuation: Boundless Bio, Inc.

Market Cap 63.92M 55.73M 52.49M 47.8M 89.62M 6.12B 89.73M 629M 242M 3.12B 240M 235M 10.07B P/E 2026 *
-1.11x
P/E 2027 * -2.87x
Enterprise Value 63.92M 55.73M 52.49M 47.8M 89.62M 6.12B 89.73M 629M 242M 3.12B 240M 235M 10.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.91%
Yield 2026 *
-
Yield 2027 * -
1 day+0.53%
1 week-0.35%
Current month+0.71%
1 month-5.67%
3 months+102.14%
6 months+146.09%
Current year+135.83%
1 week 2.75
Extreme 2.75
2.87
1 month 2.75
Extreme 2.75
3.16
Current year 0.96
Extreme 0.9612
3.16
1 year 0.96
Extreme 0.9612
3.16
3 years 0.96
Extreme 0.9612
15.24
5 years 0.96
Extreme 0.9612
15.24
10 years 0.96
Extreme 0.9612
15.24
Manager TitleAgeSince
Director of Finance/CFO 64 01/06/2021
President 55 01/07/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 01/12/2018
Director/Board Member 53 05/01/2022
Director/Board Member 53 02/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 A
Tang Capital Management LLC
SellCompany -18,300 0.0814%
7/21/26 A
Tang Capital Management LLC
BuyCompany 2,975 0.0132%
7/16/26 A
Tang Capital Management LLC
BuyCompany 18,491 0.0823%
Change 5-day change 1-year change 3-year change Capi.($)
+0.53%-0.35%+150.44% - 63.92M
+4.98%+11.06%+54.45%+109.45% 70.88B
-0.39%+1.66%+38.84%+78.01% 62.49B
+5.26%+12.77%+40.29%+26.34% 26.34B
+1.09%-3.00%-16.20%+361.43% 26.21B
+2.21%-0.81%-0.67%-7.87% 24.13B
0.00%+6.81%+24.48%-11.44% 20.72B
-2.54%-10.16%+149.64%+313.93% 15.69B
-1.90%+1.58%+44.26%+164.60% 14.46B
-5.52%-8.36%-11.62%+822.40% 14.24B
Average +0.40%+1.69%+47.39%+206.32% 27.52B
Weighted average by Cap. +1.48%+2.90%+37.23%+150.42%

Financials

2026 *2027 *
Net sales - -
Net income -57.3M -49.96M -47.05M -42.85M -80.34M -5.49B -80.44M -564M -217M -2.8B -215M -210M -9.02B -71.9M -62.69M -59.04M -53.77M -101M -6.89B -101M -707M -273M -3.51B -270M -264M -11.32B
Net Debt - -
Logo Boundless Bio, Inc.
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Employees
28
Date Price Change Volume
21/09/26 $2.830 +0.71% 120,159
18/09/26 $2.810 +0.36% 346,379
17/09/26 $2.800 -0.71% 92,212
16/09/26 $2.820 +0.36% 102,234
15/09/26 $2.810 -1.06% 23,226
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.810USD
Average target price
4.000USD
Spread / Average Target
+42.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!